Summary
The response of serum immunoreactive gastric inhibitory polypeptide (IR-GIP) and immunoreactive insulin (IRI) to a liquid mixed test meal, glucose or fat has been examined in obese subjects before and after starvation or reduced caloric intake (800 calories). Basal serum levels of IR-GIP increased significantly during starvation of obese persons and remained elevated over the whole starvation period while basal serum IRI levels decreased. The exaggerated IR-GIP response of obese subjects with normal or pathological glucose tolerance to a test meal and of obese subjects with glucose intolerance to 100 g glucose ingestion decreased significantly after starvation or food restriction. Simultaneously, the serum IRI response decreased. The exaggerated IR-GIP response of obese subjects to oral triglycerides which did not affect serum IRI or glucose levels was also significantly decreased after food restriction. The IR-GIP response of obese subjects to a test meal was already reduced after 5 days of food restriction together with an improved glucose tolerance. At this stage the IRI response was unchanged. After weight reduction in obese subjects there was a significant decrease of the IRI response to oral but not to intravenous glucose, while the glucose response decreased irrespectively of the mode of glucose administration. The IR-GIP response decreased only after oral glucose. The data are compatible with the hypothesis that the exaggerated IR-GIP response of obese subjects to oral glucose or fat load is secondary to the increased food intake and that changes in IRI response to oral glucose are related to changes in IR-GIP response.
Article PDF
Similar content being viewed by others
References
Kalkhoff, R. K., Kim, H. J., Cerletty, J., Ferrou, CA.: Metabolic effects of weight loss in obese subjects. Changes in plasma substrate levels, insulin and growth hormone responses. Diabetes20, 83–91 (1971)
Farrant, P. C., Neville, R. W. J., Stewart, G. A.: Insulin release in response to oral glucose in obesity: The effect of reduction of body weight. Diabetologia5, 198–200 (1969)
Bagdade, J. D., Porte, Jr., D., Brunzell, J. D., Bierman, E. L.: Basal and stimulated hyperinsulinism: reversible metabolic sequelae of obesity. J. Lab. Clin. Med.83, 563–569 (1974)
Bar, R. S., Gordon, P., Roth, J., Kahn, R., De Meyts, P.: Fluctuations in the affinity and concentration of insulin receptors on circulating monocytes of obese patients. Effects of starvation, refeeding, and dieting. J. Clin. Invest.58, 1123–1135 (1976)
Sims, E. A. H., Danforth, E., Horton, E. S., Bray, G. A., Glennon, J. A., Salans, L. B.: Endocrine and metabolic effects of experimental obesity in man. Recent Prog. Horm. Res.29, 457–496 (1973)
Mahler, R. J.: The relationship between eating and obesity. Acta Diabetol. Lat.9 [suppl. 1], 449–465 (1972)
Brown, J. C., Dryburgh, J. R., Ross, S. A., Dupré, J.: Identification and actions of gastric inhibitory polypeptide. Recent Prog. Horm. Res.31, 487–532 (1975)
Cleator, J. G.M., Gourlay, R. H.: Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances. Am. J.Surg.130, 128–135 (1975)
Pederson, R. A., Schubert, H. E., Brown, J. C.: Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog. Diabetes24, 1050–1056 (1975)
Crockett, S. E., Cataland, S., Falko, J. M., Mazzaferri, E. L.: The insulinotropic effect of endogenous gastric inhibitory polypeptide in normal subjects. J. Clin. Endocrinol. Metab.42, 1098–1103 (1976)
Schauder, P., Brown, J. C., Frerichs, H., Creutzfeldt, W.: Gastric inhibitory polypeptide: effect on glucose-induced insulin release from isolated rat pancreatic islets in vitro. Diabetologia11, 483–484 (1975)
Pederson, R. A., Brown, J. C.: The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology99, 780–785 (1976)
Creutzfeldt, W., Ebert, R., Willms, B., Frerichs, H., Brown, J. G.: Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels. Diabetologia14, 15–24 (1978)
Ebert, R., Willms, B., Brown, J. C., Creutzfeldt, W.: Serum gastric inhibitory polypeptide (GIP) levels in obese subjects and after weight reduction. Eur. J. Clin. Invest.6, 327 (1976)
Köbberling, J., Creutzfeldt, W.: Comparison of different methods for the evaluation of the oral glucose tolerance test. Diabetes19, 870–877 (1970)
Documenta Geigy Scientific Tables, 6th ed., p. 624. Manchester: Geigy 1962
Creutzfeldt, W., Ebert, R., Arnold, R., Frerichs, H., Brown, J. C.: Gastric inhibitory polypeptide (GIP), gastrin, and insulin: response to test meal in coeliac disease and after duodenopancreatectomy. Diabetologia12, 279–286 (1976)
Melani, F., Ditschuneit, H., Bartelt, K. M., Friedrich, H., Pfeiffer, E. F.: Über die radioimmunologische Bestimmung von Insulin im Blut. Klin. Wochenschr.43, 1000–1007 (1965)
Kuzio, M., Dryburgh, J. R., Malloy, K. M., Brown, J. C.: Radioimmunoassay for gastric inhibitory polypeptide. Gastroenterology66, 357–364 (1974)
Stern, D. H., Walsh, J. H.: Gastrin release in postoperative ulcer patients: evidence for release of duodenal gastrin. Gastroenterology64, 363–369 (1973)
Rosensweig, N. S., Stifel, F. B., Herman, R. H., Zakim, D.: The dietary regulation of the glycolytic enzymes. II. Adaptive changes in human jejunum. Biochim. Biophys. Acta170, 228–234 (1968)
Grey, N. J., Kipnis, D. M.: Effect of diet composition on the hyperinsulinemia of obesity. N. Engl. J. Med.285, 827–831 (1971)
Ogilvie, R.: Sugar tolerance in obese subjects: a review of 65 cases. Q.J.Med.28, 345–358 (1935)
Jackson, I. M. D., McKiddie, P. T., Buchanan, K. D.: The effect of prolonged fasting on carbohydrate metabolism: Evidence of heterogenicity in obesity. J. Endocrinol.40, 259–260 (1968)
Tzagournis, M., Skillman, T. G.: Glucose intolerance mechanisms after starvation. Metabolism19, 170–178 (1970)
Jackson, R. A., Moloney, M., Lowy, C., Wright, A. D., Hartog, M., Pilkington, T.R. E., Fraser, T. R.: Differences between metabolic responses to fasting in obese diabetic and obese nondiabetic subjects. Diabetes20, 214–227 (1971)
Ebert, R., Frerichs, H., Creutzfeldt, W.: Serum gastric inhibitory polypeptide (GIP) response in patients with maturity onset diabetes and in juvenile diabetes. Diabetologia12, 388 (1976)
Gepts, W.: Contribution à l'étude morphologique des îlots de Langerhans au cours du diabètes. Bruxelles: Les éditions “Acta Medica belgica” 1957
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Willms, B., Ebert, R. & Creutzfeldt, W. Gastric inhibitory polypeptide (GIP) and insulin in obesity: II. Reversal of increased response to stimulation by starvation or food restriction. Diabetologia 14, 379–387 (1978). https://doi.org/10.1007/BF01228132
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01228132